Clinical Trials Logo

Metastatic Pancreatic Cancer clinical trials

View clinical trials related to Metastatic Pancreatic Cancer.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06361888 Not yet recruiting - Clinical trials for Metastatic Pancreatic Cancer

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Start date: May 31, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

To evaluate the efficacy of Surufatnib combined withcamrelizumab, nab-paclitaxel, and gemcitabine versus nab-paclitaxel plus gemcitabine as the first-line treatment in metastatic pancreatic cancer

NCT ID: NCT05940844 Not yet recruiting - Clinical trials for Metastatic Breast Cancer

Study of OB-002 in Patients With Refractory Metastatic Cancer

Start date: January 2024
Phase: Phase 1
Study type: Interventional

This is an open-label, non-randomized trial with OB-002 monotherapy dose escalation followed by a dose expansion in patients with metastatic colorectal, pancreatic, gastric, breast, or urothelial cancer who have progressed on two or more treatment regimens.

NCT ID: NCT05138159 Not yet recruiting - Clinical trials for Metastatic Pancreatic Cancer

A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen

Start date: December 1, 2021
Phase: Phase 2
Study type: Interventional

This is a single arm, open label Phase II clinical trial to evaluate the efficacy and safety of donafenib combined with S-1 in treating Patients with metastatic pancreatic cancer after chemotherapy with Nab-paclitaxel plus gemcitabine regimen.

NCT ID: NCT04901741 Not yet recruiting - Clinical trials for Metastatic Pancreatic Cancer

Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer

OPTIMUS
Start date: June 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to provide a go/no-go decision for a randomized expansion study by assessing the disease control rate (DCR) at 6 weeks for the combination of olaptesed pegol on top of pembrolizumab and (Arm 1) nanoliposomal irinotecan, 5-FU and leucovorin or (Arm 2) gemcitabine and nab-paclitaxel, to assess safety and tolerability and time-to-event endpoints.

NCT ID: NCT02863367 Not yet recruiting - Clinical trials for Metastatic Pancreatic Cancer

A One-Arm Exploratory Clinical Trial of Apatinib Plus Gemcitabine in Patients With Advanced Metastatic Pancreatic Cancer

OECTAPGAMPC
Start date: August 2016
Phase: Phase 2
Study type: Interventional

Evaluate the efficacy and safety of Apatinib (500mg/d) with gemcitabine(1000mg/m2) in advanced metastatic pancreatic cancer.